Vanguard Group
BBIO icon

Vanguard Group’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.29B Buy
16,862,691
+30,632
+0.2% +$2.01M 0.02% 619
2025
Q3 		$874M Buy
16,832,059
+347,074
+2% +$16.9M 0.01% 771
2025
Q2 		$712M Buy
16,484,985
+1,584,840
+11% +$57.6M 0.01% 831
2025
Q1 		$515M Sell
14,900,145
-177,770
-1% -$5.99M 0.01% 974
2024
Q4 		$414M Buy
15,077,915
+879,059
+6% +$22.7M 0.01% 1151
2024
Q3 		$362M Buy
14,198,856
+144,108
+1% +$3.78M 0.01% 1219
2024
Q2 		$356M Buy
14,054,748
+832,622
+6% +$22.8M 0.01% 1164
2024
Q1 		$409M Buy
13,222,126
+421,832
+3% +$14.3M 0.01% 1109
2023
Q4 		$517M Buy
12,800,294
+1,524,313
+14% +$45.8M 0.01% 951
2023
Q3 		$297M Sell
11,275,981
-409,016
-4% -$11.6M 0.01% 1212
2023
Q2 		$201M Sell
11,684,997
-378,259
-3% -$5.69M ﹤0.01% 1472
2023
Q1 		$200M Buy
12,063,256
+1,471,801
+14% +$17.2M 0.01% 1456
2022
Q4 		$80.7M Buy
10,591,455
+587,184
+6% +$5.62M ﹤0.01% 1923
2022
Q3 		$99.4M Buy
10,004,271
+108,734
+1% +$1.13M ﹤0.01% 1787
2022
Q2 		$89.9M Buy
9,895,537
+471,425
+5% +$3.94M ﹤0.01% 1889
2022
Q1 		$95.7M Buy
9,424,112
+92,429
+1% +$949K ﹤0.01% 1966
2021
Q4 		$156M Sell
9,331,683
-103,729
-1% -$4.39M ﹤0.01% 1745
2021
Q3 		$442M Sell
9,435,412
-1,893,717
-17% -$102M 0.01% 1050
2021
Q2 		$691M Buy
11,329,129
+1,987,943
+21% +$114M 0.02% 800
2021
Q1 		$575M Buy
9,341,186
+2,899,874
+45% +$190M 0.02% 871
2020
Q4 		$458M Buy
6,441,312
+146,194
+2% +$7.05M 0.01% 925
2020
Q3 		$236M Buy
6,295,118
+508,600
+9% +$16M 0.01% 1173
2020
Q2 		$189M Buy
5,786,518
+3,417,387
+144% +$104M 0.01% 1307
2020
Q1 		$68.7M Buy
2,369,131
+228,135
+11% +$7.07M ﹤0.01% 1710
2019
Q4 		$75M Buy
2,140,996
+548,046
+34% +$15.2M ﹤0.01% 1908
2019
Q3 		$34.2M Buy
1,592,950
+1,505,668
+1,725% +$41.7M ﹤0.01% 2241
2019
Q2 		$2.35M Buy
+87,282
New +$2.38M ﹤0.01% 3426

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group's BBIO Position: Q4 2025 in Review

Vanguard Group increased its BridgeBio Pharma (BBIO) stake by 0.18% in Q4 2025, buying an estimated $2.01M and bringing the position to 16,862,691 shares worth $1.29B. The position accounts for 0.02% of the portfolio, ranked #619.

Vanguard Group first reported a position in BBIO in Q2 2019 and has held it in 27 quarters since. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Vanguard Group held 16,862,691 shares of BridgeBio Pharma worth $1.29B as of Q4 2025.
  • Vanguard Group bought 30,632 BridgeBio Pharma shares in Q4 2025, an estimated $2.01M.
  • BridgeBio Pharma made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #619 holding.
  • Vanguard Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 27 quarters since.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.